Immunology: Fundamentals of Antibody Structure
Executive Abstract
Immunology examines the immune system’s mechanisms for defending against pathogens and maintaining physiological homeostasis. Antibodies—also termed immunoglobulins (Ig)—constitute crucial adaptive immunity components, functioning as Y-shaped glycoproteins produced by B cells that recognize and neutralize foreign substances (antigens) with remarkable specificity. Understanding antibody structure is fundamental to immunology, as molecular architecture directly enables functional diversity including neutralization, opsonization, complement activation, and agglutination. This paper provides comprehensive examination of antibody structural organization spanning the Fab (antigen-binding fragment) and Fc (crystallizable fragment) regions, the five major isotypes (IgG, IgA, IgM, IgE, IgD) with their distinct properties and physiological roles, the molecular basis of antigen-antibody interactions through complementarity-determining regions, and clinical applications ranging from monoclonal antibody therapeutics to diagnostic immunoassays. The synthesis connects structural principles to functional consequences, therapeutic innovations, and the extraordinary specificity enabling adaptive immunity’s precision targeting of virtually any molecular pattern.
Context & Positioning Statement
This paper exists at the intersection of molecular immunology, structural biology, and clinical medicine. While introductory immunology courses present antibodies as key immune molecules, deep understanding of their structural organization—how four polypeptide chains fold into functional domains, how variable regions create antigen specificity, how constant regions determine effector functions—remains essential for comprehending adaptive immunity, vaccine responses, autoimmune pathology, and therapeutic antibody design. The work addresses the gap between abstract descriptions of “antibodies recognize antigens” and mechanistic understanding of how molecular structure enables this recognition and subsequent immune activation.
Within the broader research ecosystem examining immune function, antibody engineering, and therapeutic development, this paper contributes synthesis of structural principles, isotype diversity, antigen-binding mechanisms, and clinical applications into coherent framework. The intellectual contribution here is integration of molecular details (domains, chains, bonds) with functional consequences (neutralization, complement activation, transplacental transfer) and therapeutic relevance (monoclonal antibodies, immunodiagnostics). For students, clinicians, and researchers engaging with immunology, this framework provides foundation for understanding everything from vaccination to cancer immunotherapy to autoimmune disease.
Background & Literature Grounding
Antibodies represent the molecular effectors of humoral (antibody-mediated) adaptive immunity. Unlike innate immunity’s broad pattern recognition, adaptive immunity generates exquisite specificity through genetic recombination creating diverse antibody repertoires capable of recognizing virtually any molecular structure. Each B cell produces antibodies of single specificity; antigen encounter triggers clonal expansion producing large populations of identical antibody-secreting plasma cells. This clonal selection mechanism, combined with somatic hypermutation refining antibody affinity, creates highly specific immune responses.
The antibody molecule’s fundamental architecture—two heavy chains paired with two light chains forming Y-shaped structure—was elucidated through pioneering protein chemistry and X-ray crystallography revealing domain organization. Each antibody contains two identical antigen-binding sites at the tips of the Y’s arms (Fab regions) and a single constant region forming the Y’s stem (Fc region). This modular design separates antigen recognition (variable domains) from effector functions (constant domains), enabling evolution of diverse isotypes sharing similar antigen-binding capacity while differing in immunological consequences.
The five major antibody classes—IgG, IgA, IgM, IgE, IgD—differ in heavy chain constant regions (γ, α, μ, ε, δ respectively) determining their biological properties: IgG provides long-lasting systemic immunity and crosses placenta; IgA dominates mucosal secretions; IgM appears first in immune responses with high avidity; IgE mediates allergic reactions and anti-parasitic immunity; IgD functions primarily as B cell receptor with unclear circulating role. These isotype differences reflect evolutionary specialization for distinct immunological niches.
Clinical applications of antibody structure knowledge span diagnostics (ELISA, Western blot, immunohistochemistry), therapeutics (monoclonal antibodies for cancer, autoimmunity, infectious disease), and vaccine development (designing immunogens eliciting protective antibody responses). Understanding how antibodies bind antigens, activate complement, engage Fc receptors on immune cells, and cross biological barriers enables rational design of these applications.
Problem Definition / Research Question
What is the molecular structure of antibodies, and how does this structure enable their diverse immunological functions? How do the Fab and Fc regions divide labor between antigen recognition and effector activation? What distinguishes the five major antibody isotypes structurally and functionally? How do complementarity-determining regions create antigen specificity while framework regions maintain structural integrity? What molecular forces govern antibody-antigen interactions? How have structural insights enabled therapeutic antibody development and diagnostic applications?
Methods / Approach
Analytical Framework
This paper synthesizes structural biology findings from X-ray crystallography and cryo-electron microscopy, immunological principles from classical and modern immunology texts, and clinical applications from therapeutic antibody literature. The framework progresses from basic structural units (chains and domains) through functional regions (Fab and Fc) to isotype diversity and finally clinical translation.
Systems Approach
Antibody function emerges from multi-level organization: primary structure (amino acid sequence), secondary structure (β-sheets forming immunoglobulin folds), tertiary structure (domain folding), quaternary structure (multi-chain assembly), and supramolecular organization (pentameric IgM, dimeric secretory IgA). Understanding requires integrating across these levels connecting sequence variation to functional diversity.
Data Sources
Evidence derives from foundational immunology texts (Janeway’s Immunobiology, Abbas Cellular and Molecular Immunology, Alberts Molecular Biology of the Cell), structural biology databases, clinical immunology resources, and therapeutic antibody development literature. Additional sources include Mayo Clinic Laboratories, NIH immunology resources, and professional immunology organizations.
Modeling Assumptions
Antibody structure determines function—molecular architecture enables antigen recognition, effector activation, and pharmacokinetics. The modular domain structure reflects evolutionary optimization balancing specificity generation (variable regions) with conserved effector functions (constant regions). Isotype diversity represents specialization for distinct immunological contexts (systemic versus mucosal, immediate versus long-term, etc.). Non-covalent forces (hydrogen bonding, electrostatic interactions, van der Waals forces, hydrophobic effects) govern antibody-antigen binding, enabling high specificity without covalent modification. Therapeutic antibodies can be rationally designed by modifying structure to optimize binding, effector functions, or pharmacological properties.
Findings / Key Insights
General Antibody Structure: Four-Chain Y-Shaped Architecture
Antibodies are glycoproteins with characteristic Y-shaped quaternary structure comprising four polypeptide chains: two identical heavy chains (~50 kDa each) and two identical light chains (~25 kDa each). These chains are held together by disulfide bonds forming stable, functional unit. Each chain is organized into domains—structural units of approximately 110 amino acids folding into characteristic immunoglobulin (Ig) fold consisting of two β-pleated sheets stabilized by disulfide bond. Heavy chains contain one variable domain (VH) and three or four constant domains (CH1, CH2, CH3, and sometimes CH4). Light chains contain one variable domain (VL) and one constant domain (CL). The pairing of heavy and light chains positions their variable domains together forming antigen-binding sites.
- The four-chain structure creates symmetry with two identical antigen-binding sites enabling bivalent binding
- Disulfide bonds provide structural stability while maintaining some flexibility at hinge region
- Domain organization modularizes function—variable domains for antigen recognition, constant domains for effector activation
- This conserved architecture across all antibodies enables predictable structure-function relationships
Fab Region: Antigen-Binding Fragment
The Fab (Fragment, Antigen-Binding) region comprises the variable domains (VH and VL) paired with first constant domains (CH1 and CL) at the arms of the Y structure. Within variable domains, three hypervariable loops called complementarity-determining regions (CDRs) create the antigen-binding site. CDR1, CDR2, and CDR3 from both heavy and light chains (six loops total) combine to form binding pocket with shape and chemical properties complementary to specific epitope on antigen. Framework regions provide structural scaffold supporting CDR loops. Each antibody molecule has two identical Fab arms enabling binding to two identical epitopes—either on same antigen molecule (increasing binding strength through avidity) or on separate antigen molecules (enabling crosslinking and agglutination).
- Antigen specificity resides in CDR sequences—different antibodies recognizing different antigens differ primarily in CDRs
- CDR3 typically contributes most to antigen binding and shows greatest sequence diversity
- Framework regions are relatively conserved, enabling therapeutic antibody “humanization” by grafting mouse CDRs onto human frameworks
- Bivalency increases functional affinity (avidity) especially for antigens with repeating epitopes
Fc Region: Crystallizable Fragment and Effector Functions
The Fc (Fragment, Crystallizable) region comprises the constant domains of heavy chains (CH2 and CH3, sometimes CH4) forming the stem of the Y structure. This region does not bind antigen but instead determines antibody’s biological activities by interacting with Fc receptors on immune cells (macrophages, neutrophils, NK cells, mast cells) and with complement system proteins. Different antibody classes have different Fc regions conferring distinct effector functions: IgG Fc binds efficiently to phagocyte Fc receptors promoting opsonization; IgE Fc binds with extremely high affinity to mast cell and basophil receptors triggering degranulation; IgA Fc enables transport across epithelial barriers; IgM Fc efficiently activates complement. The Fc region also determines antibody half-life, tissue distribution, and transplacental transfer.
- Fc region determines what happens after antibody binds antigen—neutralization alone versus immune cell recruitment or complement activation
- Therapeutic antibodies can be engineered to enhance or reduce Fc effector functions for specific applications
- Fc receptor polymorphisms influence individual responses to antibody-based immunotherapies
- Neonatal Fc receptor (FcRn) binding determines IgG’s long half-life (~21 days) compared to other proteins
The Hinge Region: Flexibility and Function
The hinge region is flexible peptide sequence connecting Fab and Fc regions, located between CH1 and CH2 domains. This region contains multiple proline residues and disulfide bonds linking the two heavy chains. The hinge provides conformational flexibility allowing the Fab arms to move relative to each other and to the Fc region, enabling antibodies to bind epitopes separated by variable distances and to simultaneously engage antigens and effector molecules. Hinge flexibility is particularly important for IgG and IgA antibodies; IgM lacks true hinge region, and IgE has very short hinge limiting flexibility.
- Hinge flexibility enables antibodies to adapt to different spatial arrangements of epitopes on antigen surfaces
- The “Y” can open or close allowing Fab arms to spread apart or come together as needed
- Hinge region is susceptible to protease cleavage—papain cuts above hinge producing intact Fab and Fc fragments, pepsin cuts below producing F(ab’)2 fragment
- Engineered antibodies sometimes modify hinge length or sequence to optimize properties
Antibody Isotypes: Structural Variations and Specialized Functions
The five major antibody classes—IgG, IgA, IgM, IgE, IgD—differ in heavy chain constant regions determining their structure and function. IgG (γ heavy chain) is most abundant in serum (75-80% of total immunoglobulin), exists as monomer, crosses placenta providing passive immunity to fetus, has long half-life (~21 days), and efficiently activates complement and binds Fc receptors. IgA (α heavy chain) predominates in mucosal secretions (saliva, tears, breast milk, intestinal fluid), exists as monomer in serum but dimer (secretory IgA) in secretions linked by J-chain and stabilized by secretory component, protects mucosal surfaces from pathogens. IgM (μ heavy chain) is first antibody produced in primary immune response, exists as pentamer linked by J-chain creating 10 antigen-binding sites, has highest avidity despite moderate affinity, most efficient at complement activation and agglutination. IgE (ε heavy chain) is present at very low serum concentrations, binds with extremely high affinity to mast cells and basophils, mediates allergic reactions through degranulation, provides defense against parasites. IgD (δ heavy chain) is expressed on immature B cells as receptor, has unclear function in serum.
- Isotype switching allows B cells to produce antibodies with same antigen specificity but different effector functions tailored to pathogen type and location
- IgG subclasses (IgG1, IgG2, IgG3, IgG4) differ further in effector functions and hinge length
- Secretory IgA’s resistance to proteases enables survival in harsh mucosal environments
- IgM’s pentameric structure compensates for lower individual binding affinity through high avidity
Antibody-Antigen Interactions: Molecular Recognition
Antibody-antigen binding relies on non-covalent forces including hydrogen bonds, electrostatic interactions between charged residues, van der Waals forces from close atomic contacts, and hydrophobic interactions burying nonpolar surfaces. The binding is highly specific—antibodies distinguish antigens differing by single amino acid or chemical group—yet reversible, allowing antibodies to release antigen after neutralization or immune complex formation. Antibodies recognize epitopes which can be linear (continuous amino acid sequences) or conformational (three-dimensional structures formed by discontinuous sequences). Affinity refers to strength of single antigen-antibody bond (KD typically 10^-7 to 10^-11 M for high-affinity antibodies). Avidity describes combined strength of multiple bonds—multivalent antibodies like IgM achieve high avidity even with moderate individual binding site affinity.
- High specificity enables immune system to distinguish self from non-self and recognize enormous diversity of pathogens
- Conformational epitope recognition means antibodies often cannot bind denatured antigens, relevant for diagnostic assays
- Affinity maturation through somatic hypermutation improves antibody affinity during immune responses
- Therapeutic antibody development optimizes both affinity (individual binding strength) and avidity (functional binding strength)
Comparison of Antibody Isotypes
| Antibody Class | Heavy Chain | Structure | Primary Functions |
|---|---|---|---|
| IgG | γ (gamma) | Monomer | Most abundant antibody (75-80% of serum Ig); provides long-term immunity; crosses placenta conferring passive immunity to fetus and newborn; activates complement; promotes opsonization; neutralizes toxins and viruses |
| IgA | α (alpha) | Monomer (serum) Dimer (secretions) |
Found in mucosal secretions (tears, saliva, breast milk, intestinal/respiratory tract secretions); protects mucosal surfaces from pathogen colonization; secretory IgA is dimer linked by J-chain and stabilized by secretory component; resistant to proteases in harsh mucosal environments |
| IgM | μ (mu) | Pentamer | First antibody produced in primary immune response; five monomers linked by J-chain creating 10 antigen-binding sites; highest avidity despite moderate individual affinity; most efficient at complement activation and agglutination; appears early in infection before IgG |
| IgE | ε (epsilon) | Monomer | Involved in allergic reactions and anti-parasitic immunity; binds with extremely high affinity to Fc receptors on mast cells and basophils; antigen crosslinking triggers degranulation releasing histamine and inflammatory mediators; present at very low serum concentrations normally |
| IgD | δ (delta) | Monomer | Acts as receptor on surface of immature B cells; role in B cell activation and differentiation; function in serum circulation remains unclear; present at low concentrations |
Clinical and Therapeutic Applications
Monoclonal Antibodies as Therapeutics
Monoclonal antibodies (mAbs) are engineered antibodies of single specificity produced by cloning single antibody-producing B cell. Therapeutic mAbs are used in cancer immunotherapy (rituximab targeting CD20 on B cell lymphomas, trastuzumab targeting HER2 on breast cancers), autoimmune disease treatment (infliximab and adalimumab blocking TNF-α in rheumatoid arthritis and inflammatory bowel disease), infectious disease (palivizumab preventing RSV infection in high-risk infants), and transplant rejection prevention. Antibody engineering techniques include humanization (grafting mouse CDRs onto human framework reducing immunogenicity), Fc modifications (enhancing or reducing effector functions), conjugation to drugs or toxins (antibody-drug conjugates), and creation of bispecific antibodies engaging two different targets simultaneously.
- Understanding antibody structure enables rational therapeutic design optimizing target binding and effector functions
- Humanized and fully human antibodies reduce immunogenicity allowing repeated dosing
- Fc engineering can enhance ADCC (antibody-dependent cellular cytotoxicity) for cancer therapy or reduce inflammation for autoimmune applications
- The therapeutic antibody market represents multi-billion dollar pharmaceutical sector with expanding applications
Antibody-Based Diagnostics
Antibodies’ exquisite specificity makes them powerful diagnostic tools. ELISA (enzyme-linked immunosorbent assay) uses antibodies to detect and quantify specific proteins in samples—applications include infectious disease serology, hormone measurement, and biomarker detection. Western blot employs antibodies to identify specific proteins separated by gel electrophoresis—used for protein characterization and confirmatory testing (e.g., HIV). Immunohistochemistry uses antibodies to visualize protein expression in tissue sections—essential for cancer diagnosis and classification. Flow cytometry uses fluorescently labeled antibodies to identify and count specific cell types—critical for immunophenotyping in leukemia/lymphoma diagnosis and immune monitoring. Pregnancy tests, COVID-19 rapid antigen tests, and numerous point-of-care diagnostics rely on antibody-antigen interactions.
- Antibody-based diagnostics enable rapid, specific detection of diseases and biomarkers
- Understanding antibody specificity helps interpret diagnostic results and troubleshoot assay problems
- Cross-reactivity (antibody binding to unintended targets) can cause false-positive results requiring validation
- Diagnostic antibody development requires optimizing sensitivity (detecting low target concentrations) and specificity (avoiding cross-reactions)
Vaccines and Antibody Responses
Vaccination aims to elicit protective antibody responses without causing disease. Understanding antibody structure informs vaccine design: antigens should contain epitopes recognized by neutralizing antibodies, vaccines should stimulate isotype switching to appropriate antibody class (IgA for mucosal pathogens, IgG for systemic pathogens), adjuvants enhance antibody responses and affinity maturation, and booster doses drive somatic hypermutation improving antibody affinity. Passive immunization with convalescent plasma or purified antibodies (immunoglobulins) provides immediate protection for immunocompromised individuals or post-exposure prophylaxis.
- Structure-based vaccine design creates immunogens displaying protective epitopes in optimal conformations
- Measuring antibody titers and neutralizing capacity assesses vaccine efficacy
- Understanding antibody-dependent enhancement (ADE) prevents vaccine designs that worsen disease
- Maternal antibodies transferred via placenta (IgG) and breast milk (IgA) protect newborns during immune system development
Discussion
Antibody structure represents elegant evolutionary solution to immunological challenge of recognizing virtually unlimited diversity of molecular patterns while maintaining limited genomic information. The four-chain architecture with modular domain organization separates antigen recognition (variable regions generated by genetic recombination) from effector functions (constant regions determining isotype-specific activities). This separation enables immune system to pair any antigen specificity with appropriate effector mechanism through isotype switching—the same anti-bacterial antibody specificity can be expressed as IgM for immediate response, IgG for long-term systemic immunity, or IgA for mucosal protection.
The structural insights enabling modern therapeutic antibody development emerged from decades of protein chemistry, X-ray crystallography, and immunological investigation. Understanding how CDR loops create binding specificity allowed grafting mouse CDRs onto human frameworks creating humanized antibodies with reduced immunogenicity. Mapping Fc region interactions with Fc receptors and complement enabled engineering antibodies with enhanced or reduced effector functions tailored to therapeutic goals. Knowledge of antibody pharmacokinetics informed strategies extending half-life or promoting tissue penetration.
The antibody isotype system reflects specialization for distinct immunological niches. IgG’s long half-life, transplacental transfer, and efficient effector functions make it ideal for sustained systemic immunity. IgA’s dimeric secretory form with protease resistance suits harsh mucosal environments. IgM’s pentameric structure with 10 binding sites provides high avidity early in immune responses before affinity maturation improves IgG responses. IgE’s extremely high-affinity Fc receptor binding enables rapid mast cell activation against parasites but also underlies allergic pathology. This diversity exemplifies how structural variation supports functional specialization.
The molecular forces governing antibody-antigen interactions—hydrogen bonds, electrostatic interactions, van der Waals forces, hydrophobic effects—create exquisite specificity while maintaining reversibility. The binding is strong enough to neutralize pathogens but reversible enough to allow antibody recycling and immune complex processing. The combination of high specificity and moderate individual binding strength (affinity) with multivalent binding (avidity) creates robust yet flexible immune recognition.
Clinical applications of antibody structure knowledge span the therapeutic and diagnostic landscape. Monoclonal antibodies targeting cancer antigens, inflammatory mediators, or infectious agents represent major pharmaceutical advance with expanding indications. Antibody-based diagnostics enable rapid, specific detection of diseases ranging from pregnancy to HIV to COVID-19. Vaccine development increasingly incorporates structural immunology designing immunogens that elicit antibodies against critical pathogen epitopes. Understanding antibody glycosylation, Fc receptor engagement, and complement activation informs therapeutic optimization.
Future directions include engineering antibodies with novel properties: bispecific antibodies simultaneously engaging two targets, antibody-drug conjugates delivering cytotoxic payloads specifically to disease cells, antibodies penetrating blood-brain barrier or intracellular compartments, and antibodies with extended half-lives or enhanced tissue distribution. Computational design combined with high-throughput screening accelerates antibody discovery and optimization. Understanding antibody structure at atomic resolution enables rational engineering previously impossible.
Applications & Future Directions
Therapeutic Development
- Next-generation antibody formats: bispecific antibodies, antibody fragments (scFv, Fab), nanobodies from camelids
- Enhanced antibody-drug conjugates with improved linker stability and payload delivery
- Fc engineering optimizing effector functions for specific applications (enhanced ADCC for cancer, reduced effector function for anti-inflammatory therapy)
- Glycoengineering modulating antibody activity through altered glycosylation patterns
- Long-acting antibodies for chronic disease management requiring infrequent dosing
Diagnostic Innovation
- Point-of-care diagnostics enabling rapid testing outside laboratory settings
- Multiplex assays detecting multiple targets simultaneously for comprehensive disease assessment
- Improved sensitivity enabling detection of rare biomarkers or early-stage disease
- Antibody-based biosensors for continuous monitoring applications
Vaccine Design
- Structure-based immunogen design displaying protective epitopes in optimal conformations
- Nanoparticle vaccines presenting antigens in multivalent arrays enhancing antibody responses
- Germline-targeting vaccines initiating affinity maturation toward broadly neutralizing antibodies
- Universal vaccine platforms adaptable to emerging pathogens
Research Directions
- High-resolution structural studies of antibody-antigen complexes informing therapeutic design
- Investigation of antibody responses to emerging pathogens enabling rapid therapeutic development
- Understanding mechanisms of antibody-dependent enhancement preventing vaccine and therapeutic complications
- Development of computational tools predicting antibody structure and binding from sequence
- Exploration of antibody responses in special populations (neonates, elderly, immunocompromised) guiding targeted interventions
Limitations
This paper provides foundational overview of antibody structure but cannot comprehensively address every structural variant, subclass, or specialized antibody type. The focus on human antibodies may not fully translate to other species with different antibody repertoires or isotype distributions. The cited references represent authoritative sources but rapidly advancing field means recent developments may not be included—readers should consult current literature for cutting-edge applications.
Antibody structure-function relationships are presented as general principles, but exceptions and context-dependent variations exist. Not all antibodies fit cleanly into described categories—natural antibodies, polyreactive antibodies, and antibodies with unusual properties challenge simplified models. The therapeutic antibody landscape evolves rapidly with novel formats and engineering approaches emerging continuously. Clinical applications described represent major categories but don’t exhaustively cover every diagnostic or therapeutic use.
Conclusion
Antibody structure represents molecular masterpiece of evolutionary engineering—four polypeptide chains assembling into Y-shaped architecture that separates antigen recognition from effector activation, enabling enormous diversity of binding specificities paired with specialized functional properties. The modular domain organization with variable regions creating antigen-binding sites through CDR loops and constant regions determining isotype-specific effector functions provides both specificity and flexibility. The five major antibody classes—IgG providing sustained systemic immunity, IgA protecting mucosal surfaces, IgM initiating early responses, IgE mediating anti-parasitic and allergic responses, IgD functioning as B cell receptor—reflect structural specialization for distinct immunological niches. Understanding these structural principles has enabled revolutionary therapeutic applications including monoclonal antibodies targeting cancer and autoimmune disease, antibody-based diagnostics detecting diseases with exquisite specificity, and structure-guided vaccine design eliciting protective antibody responses. As structural immunology advances through improved crystallographic techniques, cryo-electron microscopy, and computational modeling, our ability to rationally engineer antibodies with optimized properties continues expanding. The antibody—this Y-shaped molecule with its complementarity-determining regions sampling molecular space, its Fc region recruiting immune effectors, its isotypes specialized for different battlegrounds—stands as both fundamental immunological tool and sophisticated therapeutic platform. In the precise geometry of its binding site, the strategic positioning of its effector domains, and the evolutionary refined architecture balancing specificity with stability, the antibody embodies adaptive immunity’s central challenge and triumph: recognizing the foreign amid the familiar, mobilizing defense without self-destruction, and remembering encounters to protect against future threats. These molecules—produced by billions in response to vaccination or infection, circulating in blood and secretions, binding pathogens with molecular precision—represent immune system’s most specific weapons and medicine’s most targeted therapies.
References
- Janeway, C. A., Travers, P., Walport, M., & Shlomchik, M. J. (2001). Immunobiology: The Immune System in Health and Disease.
- Alberts, B., et al. (2015). Molecular Biology of the Cell.
- Abbas, A. K., Lichtman, A. H., & Pillai, S. (2020). Cellular and Molecular Immunology.
- Mayo Clinic Laboratories. Immunoglobulins. https://news.mayocliniclabs.com
- National Center for Biotechnology Information. Antibody Structure and Function. https://www.ncbi.nlm.nih.gov/books/NBK519007/
- Binding Site USA. Antibody Structure and Function. https://biausa.org/
Keywords
Citation Export
Cite this publication
APA
Gwyn, B. R. (2024). Immunology: Fundamentals of Antibody Structure (Publication ID BRG-PUB-4345, version 1.0). Bailey Gwyn Publications Repository. https://www.baileygwyn.xyz/publications/papers/immunology-antibody-structure/
MLA
Gwyn, Bailey Reid. "Immunology: Fundamentals of Antibody Structure." Bailey Gwyn Publications Repository, 2024, Publication ID BRG-PUB-4345, version 1.0, https://www.baileygwyn.xyz/publications/papers/immunology-antibody-structure/. Accessed July 12, 2026.
Chicago
Gwyn, Bailey Reid. "Immunology: Fundamentals of Antibody Structure." Bailey Gwyn Publications Repository, 2024. Publication ID BRG-PUB-4345, version 1.0. https://www.baileygwyn.xyz/publications/papers/immunology-antibody-structure/.
BibTeX
@misc{Gwyn2024ImmunologyFundamentalsofAntibody,
author = {Gwyn, Bailey Reid},
title = {Immunology: Fundamentals of Antibody Structure},
year = {2024},
howpublished = {https://www.baileygwyn.xyz/publications/papers/immunology-antibody-structure/},
note = {Bailey Gwyn Publications Repository; Publication ID BRG-PUB-4345, version 1.0}
}
RIS
TY - GEN AU - Gwyn, Bailey Reid PY - 2024 TI - Immunology: Fundamentals of Antibody Structure UR - https://www.baileygwyn.xyz/publications/papers/immunology-antibody-structure/ PB - Bailey Gwyn Publications Repository ID - BRG-PUB-4345 N1 - Version 1.0; accessed July 12, 2026 ER -